Merck Zocor Revised Myopathy Warning Says Risk Is Dose-Related
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The incidence of myopathy/rhabdomyolysis for Merck’s Zocor is dose-related, with a more than ten-fold greater risk for the highest dose of the drug, revised labeling indicates.